<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02276547</url>
  </required_header>
  <id_info>
    <org_study_id>047-CPT-001</org_study_id>
    <nct_id>NCT02276547</nct_id>
  </id_info>
  <brief_title>Early Feasibility Study of the Neovasc Tiara™ Mitral Valve System</brief_title>
  <acronym>TIARA-I</acronym>
  <official_title>Early Feasibility Study of the Neovasc Tiara™ Mitral Transcatheter Heart Valve With the Tiara™ Transapical Delivery System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neovasc Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neovasc Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and initial performance of the Neovasc
      Tiara Mitral Transcatheter Heart Valve with the Tiara Transapical Delivery System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an international, multicenter, single arm, prospective, Early Feasibility Clinical
      Study to evaluate the safety and performance of the Neovasc Tiara Mitral Valve System in
      subjects with symptomatic severe mitral regurgitation requiring mitral valve replacement who
      are at high risk for open chest surgery.

      A maximum of 30 subjects will be implanted in this study at a maximum of 10 sites. A maximum
      of 15 subjects will be implanted in the United States.

      Subjects satisfying the inclusion criteria and exclusion criteria will be enrolled to receive
      the Neovasc Tiara Mitral Transcatheter Heart Valve with the Tiara Delivery System via a
      transcatheter mitral valve replacement (TMVR) procedure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from all-cause mortality and major adverse events defined as disabling stroke, myocardial infarction, renal failure requiring dialysis, life-threatening bleeding, and cardiac surgical or transcatheter reintervention</measure>
    <time_frame>30 days from the implant procedure or hospital discharge (whichever is later)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with all-cause mortality, disabling stroke, myocardial infarction, renal failure requiring dialysis, life-threatening bleeding and cardiac surgical or transcatheter reintervention</measure>
    <time_frame>30 days, 90 days, 180 days and annually to five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual 30 day rates of device and procedure related major adverse events</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with progression of heart failure</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success; delivery and deployment of the device in the correct position and retrieval of delivery catheter</measure>
    <time_frame>Post procedure, discharge, 30 days, 90 days, 180 days and annually for five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance measured by NYHA Functional Class, 6 Minute Walk Test and the Kansas City Cardiomyopathy Questionnaire comparing baseline to each time period</measure>
    <time_frame>30 days, 90 days, 180 days and annually for five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and out of hospital</measure>
    <time_frame>At one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter mitral valve replacement with the TIARA valve and transapical delivery system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mitral valve replacement</intervention_name>
    <description>Transcatheter mitral valve replacement</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>TIARA Mitral Transcatheter Heart Valve, TIARA Transapical Delivery System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe symptomatic mitral regurgitation (Stage D)

          -  High surgical risk for open mitral valve surgery

          -  Subject meets the anatomical eligibility criteria for available size(s)

          -  NYHA Class III or IV heart failure

        Exclusion Criteria:

          -  DMR deemed by the heart team to be operable.

          -  Prohibitive risk, deemed too frail or listed for cardiac transplant.

          -  Unsuitable cardiac structure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anson Cheung, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Josh D Carlson</last_name>
    <phone>855-802-5180</phone>
    <phone_ext>310</phone_ext>
    <email>Jcarlson@neovasc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Naomi J Tatarek, BSN</last_name>
    <phone>855-802-5180</phone>
    <phone_ext>301</phone_ext>
    <email>Ntatarek@neovasc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>312-926-4000</phone>
      <email>heartresearch@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick M McCarthy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Hill</last_name>
      <phone>313-916-7430</phone>
      <email>ahill13@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Adam Greenbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Lasala, MD</last_name>
      <phone>855-825-8457</phone>
    </contact>
    <investigator>
      <last_name>John Lasala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Jordan</last_name>
      <phone>206-616-6768</phone>
      <email>jordank1@cardiology.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Reisman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>B 2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Verheye, MD, PhD</last_name>
      <phone>32 49 6862375</phone>
      <email>stefan.verheye@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Stefan Verheye, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nasim Boroumand</last_name>
      <phone>780-407-2667</phone>
    </contact>
    <investigator>
      <last_name>Steven Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miroslav Svetik, MD, IMG</last_name>
      <phone>604-806-9981</phone>
      <email>msvetik@providencehealth.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Anson Cheung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Fox, BA, RRT</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>35031</phone_ext>
      <email>stephanie.fox@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Bob Kiaii, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.neovasc.com</url>
    <description>Company website with product information</description>
  </link>
  <reference>
    <citation>De Backer O, Piazza N, Banai S, Lutter G, Maisano F, Herrmann HC, Franzen OW, Søndergaard L. Percutaneous transcatheter mitral valve replacement: an overview of devices in preclinical and early clinical evaluation. Circ Cardiovasc Interv. 2014 Jun;7(3):400-9. doi: 10.1161/CIRCINTERVENTIONS.114.001607. Review.</citation>
    <PMID>24944303</PMID>
  </reference>
  <reference>
    <citation>Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM 3rd, Thomas JD, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Creager MA, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Stevenson WG, Yancy CW; American College of Cardiology; American College of Cardiology/American Heart Association; American Heart Association. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2014 Jul;148(1):e1-e132. doi: 10.1016/j.jtcvs.2014.05.014. Epub 2014 May 9. Review. Erratum in: J Thorac Cardiovasc Surg. 2014 Oct 21;64(16):1763. Dosage error in article text.</citation>
    <PMID>24939033</PMID>
  </reference>
  <reference>
    <citation>Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB; Valve Academic Research Consortium-2. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg. 2013 Jan;145(1):6-23. doi: 10.1016/j.jtcvs.2012.09.002. Epub 2012 Oct 16. Review.</citation>
    <PMID>23084102</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>October 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2014</study_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitral</keyword>
  <keyword>Regurgitation</keyword>
  <keyword>Heart valve</keyword>
  <keyword>Transcatheter</keyword>
  <keyword>Transapical</keyword>
  <keyword>Functional</keyword>
  <keyword>Degenerative</keyword>
  <keyword>Symptomatic, severe mitral valve regurgitation, high risk for open mitral valve surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

